(MT Newswires) -- Bristol-Myers (BMY) CEO Christopher Boerner discusses the company's transition, marked by a series of transactions and the development of new drugs, particularly in neuroscience and oncology. He talks about growth prospects, the pipeline of 16 new drugs in development between now and the end of the decade, and the return of capital to shareholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.48 USD | +1.47% | +0.95% | -19.16% |
Jun. 07 | Geron shares surge after U.S. FDA approves blood disorder drug | RE |
Jun. 05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.16% | 84.08B | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology